MalnutritionNCT06206694
Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients
An observational study of Malnutrition and Oxidative Stress, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.
Trial summary
Background YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 levels with nutrition status, inflammation, and body composition in a cohort of hemodialysis patients Methods We plan to… Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Malnutrition, Oxidative Stress
- How many people
- 226 participants
- Where
- 1 siteTaiwan
- Study dates
- 2 May 2024to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients have to be at least 20-years-old and hemodialysis (HD) for at least 3 months.
Who may be able to join
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Who cannot join
- heart failure
- infection
- cirrhosis
- respiratory disease
- nephrotic syndrome
- malignancy
Show all 9Show fewer
- chronic liver disease
- severe inflammation
- None of the patients are receiving surgical operations or hospitalized in recent 3 months.
Trial locations and contacts
1 site in 1 country.
About this study
Background
YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 levels with nutrition status, inflammation, and body composition in a cohort of hemodialysis patients
Methods
We plan to recruit 400 prevalent HD patients. Their baseline serum YKL-40 levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, and nutritional indices will be measured.
Read the detailed description
Study Design and Patients
Patients This is a prospective observational study. The patients will be recruited from HD patients at dialysis units of Tungs Taichung Metroharbour Hospital, which is an outpatient facility. The study inclusion criteria of participants are those maintain on HD therapy for at least 3 months prior to enrollment and being in stable condition without co-morbidities such as heart failure, infection, cirrhosis, respiratory disease, nephrotic syndrome, malignancy, chronic liver disease, or severe inflammation. None of the patients are receiving surgical operations or hospitalized in recent 3 months. In this study, written informed consent will be obtained from all participants. The study protocol will be send to the institutional review board of Tungs Taichung Metroharbour Hospital for approval. The study will be registered to the ClinicalTrial. Gov. Registry and will fully adhered to the guidelines of the Declaration of Helsinki
Methodology
Laboratory measurements Blood samples will be collected before dialysis session. Serum biochemistry such as albumin, urea nitrogen, uric acid, creatinine, total cholesterol, triacylglycerol levels, total ion binding capacity (TIBC), 25-hydroxyvitamin D, hemoglobin, and white blood count are measured employing standard laboratory techniques with the use of an automatic analyzer. Serum prealbumin and high-sensitivity C-reactive protein (hs-CRP) are quantified by nephelometry. YKL-40 and interleukin-6 (IL-6) were quantified by a double-sided sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R\&D Systems ; Minneapolis, MN, USA).
Fasting glucose levels were measured, after overnight fast and classified according to the American Diabetes Association (ADA) standards [29]. In addition, the serum insulin level, and hemoglobin A1c level are measured. The assessment of insulin resistance is done using the HOMA-IR index [30]: HOMA - IR = fasting glucose (in mmol/l) × fasting insulin (in µU/ml) / 22.5 Serum insulin, vaspin, and adiponectin level is measured by a commercially available ELISA kit following the manufacturer's instructions. Markers of oxidative stress such as total antioxidant capacity [TAC]), serum advanced oxidation protein products (AOPP) and serum CML (a component of AGEs) will also be measured.
Evaluation of nutritional status and body composition
Anthropometric measures including body weight, body mass index (BMI), waist and hip circumference, mid-arm circumference, and the waist-hip ratio (WHR) will be obtained. BMI is determined by the standard formula and further categorized according to the Asia Pacific version of the WHO classification [31-32]. According to this system, BMI<18 kg/m2 is underweight; 18 to 22.9 is normal weight; 23 to 24.9 is marginal overweight; 25 to 29.9 is overweight; and greater than 30 is obesity [27, 28]. Lastly, the conicity index at baseline is determined to quantify the degree of central obesity [33].
Patients' nutrition status is determined by their serum albumin and pre-albumin levels, Subjective Global Assessment (SGA) score, normalized protein nitrogen appearance (NPNA), and fat-free edema-free body mass (FEBM). The 4-item 7-point SGA scoring system is employed [34]. NPNA was calculated using the modifed Bergstrom's formula [35]. FEBM was calculated using the creatinine kinetic method following the Forbes and Brunining formula [36], and reported as a percentage of their ideal body weight.
We use the multi-frequency bio-impedance spectroscopy device (Body Composition Monitor, Fresenius Medical Care, Germany) as described previously [36, 37]. In this study, the data on lean tissue mass (LTM), adipose tissue mass (ATM), the volume of over-hydration (OH), and the extracellular-tointracellular volume (E: I) ratio will be analyzed.
Statistical analysis All variables were analysed using a Kolmogorov-Smirnov test to classify them as normally or non-normally distributed. Values are given as mean [standard deviation (SD)] or median (IQR). Univariate analysis is performed to examine the relationships between YKL-40 and other parameters employing Spearman's rank correlation coefficient. Multivariate analysis is performed for parameters showing significant differences. Potential confounding factors for increased YKL-40 are assessed using a multiple regression analysis model based on general variables, inflammatory markers and correlations with malnutrition (p<0.10). Two-sided P values of <0.05 are considered to be statistically significant in all analyses. All statistical analyses were performed with the SPSS 23.0 statistical package (SPSS, Chicago, IL, USA). A p-value <0.05 is considered statistically significant.
- Conditions
- Malnutrition, Oxidative Stress
- Keywords
- YKL-40, nutrition status, hemodialysis patients, inflammation
- Medical subject headings
- Malnutrition, Inflammation
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of biomarkers of YKL40
YKL40 is also reportedly useful as an inflammation marker in HD patients
Measured: 1 years
Evaluation of nutritional status and body composition
Malnutrition, with a prevalence between 40% and 75% in maintenance hemodialysis patients is the most important risk factor for morbidity, the quality of life, all-cause mortality and cardiovascular mortality.
Measured: 1 years
Secondary outcomes (7)
Analysis of biomarkers of IL-6
The IL-6 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
vaspin
The vaspin was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
insulin
The insulin was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
adiponectin
The adiponectin was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
total antioxidant capacity
Total antioxidant capacityassay is useful to assay antioxidant levels in serum
Measured: 1 years
AOPP
The IL-6 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Nε-Carboxymethyllysine (CML)
The Nε-Carboxymethyllysine (CML) was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2024
- Study start2 May 2024
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MalnutritionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 226 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tungs' Taichung Metroharbour Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paik Seong Lim, PhD, Principal investigator, Tungs' Taichung Metroharbour Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06206694
- Sponsor's protocol ID
- 112049
- Status last verified
- Jun 2025
- First submitted
- 4 Jan 2024
- Last updated
- 6 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum YKL-40 Levels is Associated With Nutritional and Oxidative Status of Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT06206694
- Acronym / sponsor ID
- 112049
- Conditions
- Malnutrition, Oxidative Stress
- Keywords
- YKL-40, nutrition status, hemodialysis patients, inflammation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 226 participants (actual)
- Lead sponsor
- Tungs' Taichung Metroharbour HospitalUniversity, hospital or other
- Study start
- 2 May 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 16 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background
YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 levels with nutrition status, inflammation, and body composition in a cohort of hemodialysis patients
Methods
We plan to recruit 400 prevalent HD patients. Their baseline serum YKL-40 levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, and nutritional indices will be measured.
Detailed description
Study Design and Patients
Patients This is a prospective observational study. The patients will be recruited from HD patients at dialysis units of Tungs Taichung Metroharbour Hospital, which is an outpatient facility. The study inclusion criteria of participants are those maintain on HD therapy for at least 3 months prior to enrollment and being in stable condition without co-morbidities such as heart failure, infection, cirrhosis, respiratory disease, nephrotic syndrome, malignancy, chronic liver disease, or severe inflammation. None of the patients are receiving surgical operations or hospitalized in recent 3 months. In this study, written informed consent will be obtained from all participants. The study protocol will be send to the institutional review board of Tungs Taichung Metroharbour Hospital for approval. The study will be registered to the ClinicalTrial. Gov. Registry and will fully adhered to the guidelines of the Declaration of Helsinki
Methodology
Laboratory measurements Blood samples will be collected before dialysis session. Serum biochemistry such as albumin, urea nitrogen, uric acid, creatinine, total cholesterol, triacylglycerol levels, total ion binding capacity (TIBC), 25-hydroxyvitamin D, hemoglobin, and white blood count are measured employing standard laboratory techniques with the use of an automatic analyzer. Serum prealbumin and high-sensitivity C-reactive protein (hs-CRP) are quantified by nephelometry. YKL-40 and interleukin-6 (IL-6) were quantified by a double-sided sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R\&D Systems ; Minneapolis, MN, USA).
Fasting glucose levels were measured, after overnight fast and classified according to the American Diabetes Association (ADA) standards [29]. In addition, the serum insulin level, and hemoglobin A1c level are measured. The assessment of insulin resistance is done using the HOMA-IR index [30]: HOMA - IR = fasting glucose (in mmol/l) × fasting insulin (in µU/ml) / 22.5 Serum insulin, vaspin, and adiponectin level is measured by a commercially available ELISA kit following the manufacturer's instructions. Markers of oxidative stress such as total antioxidant capacity [TAC]), serum advanced oxidation protein products (AOPP) and serum CML (a component of AGEs) will also be measured.
Evaluation of nutritional status and body composition
Anthropometric measures including body weight, body mass index (BMI), waist and hip circumference, mid-arm circumference, and the waist-hip ratio (WHR) will be obtained. BMI is determined by the standard formula and further categorized according to the Asia Pacific version of the WHO classification [31-32]. According to this system, BMI<18 kg/m2 is underweight; 18 to 22.9 is normal weight; 23 to 24.9 is marginal overweight; 25 to 29.9 is overweight; and greater than 30 is obesity [27, 28]. Lastly, the conicity index at baseline is determined to quantify the degree of central obesity [33].
Patients' nutrition status is determined by their serum albumin and pre-albumin levels, Subjective Global Assessment (SGA) score, normalized protein nitrogen appearance (NPNA), and fat-free edema-free body mass (FEBM). The 4-item 7-point SGA scoring system is employed [34]. NPNA was calculated using the modifed Bergstrom's formula [35]. FEBM was calculated using the creatinine kinetic method following the Forbes and Brunining formula [36], and reported as a percentage of their ideal body weight.
We use the multi-frequency bio-impedance spectroscopy device (Body Composition Monitor, Fresenius Medical Care, Germany) as described previously [36, 37]. In this study, the data on lean tissue mass (LTM), adipose tissue mass (ATM), the volume of over-hydration (OH), and the extracellular-tointracellular volume (E: I) ratio will be analyzed.
Statistical analysis All variables were analysed using a Kolmogorov-Smirnov test to classify them as normally or non-normally distributed. Values are given as mean [standard deviation (SD)] or median (IQR). Univariate analysis is performed to examine the relationships between YKL-40 and other parameters employing Spearman's rank correlation coefficient. Multivariate analysis is performed for parameters showing significant differences. Potential confounding factors for increased YKL-40 are assessed using a multiple regression analysis model based on general variables, inflammatory markers and correlations with malnutrition (p<0.10). Two-sided P values of <0.05 are considered to be statistically significant in all analyses. All statistical analyses were performed with the SPSS 23.0 statistical package (SPSS, Chicago, IL, USA). A p-value <0.05 is considered statistically significant.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients have to be at least 20-years-old and hemodialysis (HD) for at least 3 months.
Key inclusion criteria (3 listed)
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Key exclusion criteria (9 listed)
- heart failure
- infection
- cirrhosis
- respiratory disease
- nephrotic syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analysis of biomarkers of YKL40
Time frame: 1 years
YKL40 is also reportedly useful as an inflammation marker in HD patients
Evaluation of nutritional status and body composition
Time frame: 1 years
Malnutrition, with a prevalence between 40% and 75% in maintenance hemodialysis patients is the most important risk factor for morbidity, the quality of life, all-cause mortality and cardiovascular mortality.
7 secondary outcomes
Analysis of biomarkers of IL-6
Time frame: 1 years
vaspin
Time frame: 1 years
insulin
Time frame: 1 years
adiponectin
Time frame: 1 years
total antioxidant capacity
Time frame: 1 years
AOPP
Time frame: 1 years
Nε-Carboxymethyllysine (CML)
Time frame: 1 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Malnutrition
RecruitingPhase 1/2
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
X-linked Hypophosphatemia
Recruiting
Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)
Diabetes Mellitus, Type 2, Nutrition Poor
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Active, not recruitingPhase 2
Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan
Environmental Enteric Dysfunction (EED), Stunting
Not yet recruitingObservational study
Biomarkers in EV Associated With Marrow Adiposity in Anorexia
Anorexia Nervosa Restricting Type, Anorexia Nervosa (DSM-IV Revised Criteria)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paik Seong Lim, PhD principal investigator
Tungs' Taichung Metroharbour Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malnutrition and Oxidative Stress, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of biomarkers of YKL40 (time frame: 1 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2025.